The DOI matches its Crossref record; 28 of the 28 references it cites were found in a registry or an index.
The phosphorylation state of Ser-129 in human α-synuclein determines neurodegeneration in a rat model of Parkinson disease
Open accessAbstract
Studies have shown that α-synuclein (α-syn) deposited in Lewy bodies in brain tissue from patients with Parkinson disease (PD) is extensively phosphorylated at Ser-129. We used recombinant Adeno-associated virus (rAAV) to overexpress human wild-type (wt) α-syn and two human α-syn mutants with site-directed replacement of Ser-129 to alanine (S129A) or to aspartate (S129D) in the nigrostriatal tract of the rat to investigate the effect of Ser-129 phosphorylation state on dopaminergic neuron pathology. Rats were injected with rAAV2/5 vectors in the substantia nigra pars compacta (SNc) on one side of the brain; the other side remained as a nontransduced control. The level of human wt or mutant α-syn expressed on the injected side was about four times the endogenous rat α-syn. There was a significant reduction of dopaminergic neurons in the SNc and dopamine (DA) and tyrosine hydroxylase (TH) levels in the striatum of all S129A-treated rats as early as 4 wk postinjection. Nigral DA pathology occurred more slowly in the wt-injected animals, but by 26 wk the wt α-syn group lost nigral TH neurons equivalent to the mutated S129A group at 8 wk. In stark contrast, we did not observe any pathological changes in S129D-treated animals. Therefore, the nonphosphorylated form of S129 exacerbates α-syn-induced nigral pathology, whereas Ser-129 phosphorylation eliminates α-syn-induced nigrostriatal degeneration. This suggests possible new therapeutic targets for Parkinson Disease.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
α-Synuclein is phosphorylated in synucleinopathy lesions
Fujiwara, H., Hasegawa, M., Dohmae, N., Kawashima, A., Masliah, E., Goldberg, M. S., Shen, J., Takio, K., & Iwatsubo, T. (2002) · Nature Cell Biology · doi:10.1038/ncb748 · Cited by 2,132
Mice Lacking α-Synuclein Display Functional Deficits in the Nigrostriatal Dopamine System
Abeliovich, A., Schmitz, Y., Fariñas, I., Choi-Lundberg, D., Ho, W.-H., Castillo, P. E., Shinsky, N., Verdugo, J. M. G., Armanini, M., Ryan, A., et al. (2000) · Neuron · doi:10.1016/s0896-6273(00)80886-7 · Cited by 1,722
Anderson, J. P., Walker, D. E., Goldstein, J. M., de Laat, R., Banducci, K., Caccavello, R. J., Barbour, R., Huang, J., Kling, K., Lee, M., et al. (2006) · Journal of Biological Chemistry · doi:10.1074/jbc.m600933200 · Cited by 1,416
α-Synuclein Blocks ER-Golgi Traffic and Rab1 Rescues Neuron Loss in Parkinson's Models
Cooper, A. A., Gitler, A. D., Cashikar, A., Haynes, C. M., Hill, K. J., Bhullar, B., Liu, K., Xu, K., Strathearn, K. E., Liu, F., et al. (2006) · Science · doi:10.1126/science.1129462 · Cited by 1,376
α-Synuclein Cooperates with CSPα in Preventing Neurodegeneration
Chandra, S., Gallardo, G., Fernández-Chacón, R., Schlüter, O. M., & Südhof, T. C. (2005) · Cell · doi:10.1016/j.cell.2005.09.028 · Cited by 966
Murphy, D. D., Rueter, S. M., Trojanowski, J. Q., & Lee, V. M.-Y. (2000) · The Journal of Neuroscience · doi:10.1523/jneurosci.20-09-03214.2000 · Cited by 836
Burger, C., Gorbatyuk, O. S., Velardo, M. J., Peden, C. S., Williams, P., Zolotukhin, S., Reier, P. J., Mandel, R. J., & Muzyczka, N. (2004) · Molecular Therapy · doi:10.1016/j.ymthe.2004.05.024 · Cited by 741
Self-citationMartin, L. J., Pan, Y., Price, A. C., Sterling, W., Copeland, N. G., Jenkins, N. A., Price, D. L., & Lee, M. K. (2006) · The Journal of Neuroscience · doi:10.1523/jneurosci.4308-05.2006 · Cited by 684
THE BIOCHEMISTRY OF PARKINSON'S DISEASE
Cookson, M. R. (2005) · Annual Review of Biochemistry · doi:10.1146/annurev.biochem.74.082803.133400 · Cited by 664
Kirik, D., Rosenblad, C., Burger, C., Lundberg, C., Johansen, T. E., Muzyczka, N., Mandel, R. J., & Björklund, A. (2002) · The Journal of Neuroscience · doi:10.1523/jneurosci.22-07-02780.2002 · Cited by 649
Self-citationChen, L., & Feany, M. B. (2005) · Nature Neuroscience · doi:10.1038/nn1443 · Cited by 618
α-synuclein acts in the nucleus to inhibit histone acetylation and promote neurotoxicity
Kontopoulos, E., Parvin, J. D., & Feany, M. B. (2006) · Human Molecular Genetics · doi:10.1093/hmg/ddl243 · Cited by 537
Constitutive Phosphorylation of the Parkinson's Disease Associated α-Synuclein
Okochi, M., Walter, J., Koyama, A., Nakajo, S., Baba, M., Iwatsubo, T., Meijer, L., Kahle, P. J., & Haass, C. (2000) · Journal of Biological Chemistry · doi:10.1074/jbc.275.1.390 · Cited by 519
Synucleins Are a Novel Class of Substrates for G Protein-coupled Receptor Kinases
Pronin, A. N., Morris, A. J., Surguchov, A., & Benovic, J. L. (2000) · Journal of Biological Chemistry · doi:10.1074/jbc.m003542200 · Cited by 387
Effect of Mutant α-Synuclein on Dopamine Homeostasis in a New Human Mesencephalic Cell Line
Lotharius, J., Barg, S., Wiekop, P., Lundberg, C., Raymon, H. K., & Brundin, P. (2002) · Journal of Biological Chemistry · doi:10.1074/jbc.m205518200 · Cited by 352
Role of α-Synuclein in Presynaptic Dopamine Recruitment
Yavich, L., Tanila, H., Vepsäläinen, S., & Jäkälä, P. (2004) · The Journal of Neuroscience · doi:10.1523/jneurosci.2559-04.2004 · Cited by 316
Aggregated α-Synuclein Mediates Dopaminergic Neurotoxicity In Vivo
Periquet, M., Fulga, T., Myllykangas, L., Schlossmacher, M. G., & Feany, M. B. (2007) · The Journal of Neuroscience · doi:10.1523/jneurosci.0285-07.2007 · Cited by 292
Cappai, R., Leck, S., Tew, D. J., Williamson, N. A., Smith, D. P., Galatis, D., Sharpies, R. A., Curtain, C. C., Ali, F. E., Cherny, R. A., et al. (2005) · The FASEB Journal · doi:10.1096/fj.04-3437fje · Cited by 257
Peng, X. M., Tehranian, R., Dietrich, P., Stefanis, L., & Perez, R. G. (2005) · Journal of Cell Science · doi:10.1242/jcs.02481 · Cited by 249 · cited 2×
“There is also evidence that -syn can modulate expression of genes involved in DA synthesis (11) and can affect enzymes involved in chromatin remodeling (12) and signal transduction (13).”
BackgroundLong-term consequences of human alpha-synuclein overexpression in the primate ventral midbrain
Eslamboli, A., Romero-Ramos, M., Burger, C., Bjorklund, T., Muzyczka, N., Mandel, R. J., Baker, H., Ridley, R. M., & Kirik, D. (2007) · Brain · doi:10.1093/brain/awl382 · Cited by 227
Self-citationFredenburg, R. A., Rospigliosi, C., Meray, R. K., Kessler, J. C., Lashuel, H. A., Eliezer, D., & Lansbury, P. T. (2007) · Biochemistry · doi:10.1021/bi7000246 · Cited by 227
Attenuation of dopamine transporter activity by α-synuclein
Wersinger, C., & Sidhu, A. (2003) · Neuroscience Letters · doi:10.1016/s0304-3940(03)00097-1 · Cited by 197
Impairment of microtubule‐dependent trafficking by overexpression of α‐synuclein
Lee, H., Khoshaghideh, F., Lee, S., & Lee, S. (2006) · European Journal of Neuroscience · doi:10.1111/j.1460-9568.2006.05210.x · Cited by 158
α-Synuclein Affects the MAPK Pathway and Accelerates Cell Death
Iwata, A., Maruyama, M., Kanazawa, I., & Nukina, N. (2001) · Journal of Biological Chemistry · doi:10.1074/jbc.m103736200 · Cited by 152
The Role of G-Protein-Coupled Receptor Kinase 5 in Pathogenesis of Sporadic Parkinson's Disease
Arawaka, S., Wada, M., Goto, S., Karube, H., Sakamoto, M., Ren, C.-H., Koyama, S., Nagasawa, H., Kimura, H., Kawanami, T., et al. (2006) · Journal of Neuroscience · doi:10.1523/jneurosci.0341-06.2006 · Cited by 142
alpha-Synuclein forms a complex with transcription factor Elk-1
Iwata, A., Miura, S., Kanazawa, I., Sawada, M., & Nukina, N. (2001) · Journal of Neurochemistry · doi:10.1046/j.1471-4159.2001.t01-1-00232.x · Cited by 101
Wakamatsu, M., Ishii, A., Ukai, Y., Sakagami, J., Iwata, S., Ono, M., Matsumoto, K., Nakamura, A., Tada, N., Kobayashi, K., et al. (2007) · Journal of Neuroscience Research · doi:10.1002/jnr.21310 · Cited by 91
Liu, C., Fei, E., Jia, N., Wang, H., Tao, R.-S., Iwata, A., Nukina, N., Zhou, J., & Wang, G. (2007) · Journal of Biological Chemistry · doi:10.1074/jbc.m700422200 · Cited by 45
Cited by
The many faces of α-synuclein: from structure and toxicity to therapeutic target
Lashuel, H. A., Overk, C. R., Oueslati, A., & Masliah, E. (2013) · Nature Reviews Neuroscience · doi:10.1038/nrn3406 · Cited by 1,622
-Synuclein in Parkinson's Disease
Stefanis, L. (2012) · Cold Spring Harbor Perspectives in Medicine · doi:10.1101/cshperspect.a009399 · Cited by 1,446
“…enhanced a-synuclein-soluble oligomers (but actually decreased a-synuclein inclusions) and neurotoxicity (Chen et al. 2005, 2009); subsequent studies have cast doubt on this notion, providing contradictory results (Gorbatyuk et al. 2008; Paleologou et al. 2008; Azeredo da Silveira et al. 2009).”
ResultWhat Genetics Tells us About the Causes and Mechanisms of Parkinson's Disease
Corti, O., Lesage, S., & Brice, A. (2011) · Physiological Reviews · doi:10.1152/physrev.00022.2010 · Cited by 611
Cellular milieu imparts distinct pathological α-synuclein strains in α-synucleinopathies
Peng, C., Gathagan, R. J., Covell, D. J., Medellin, C., Stieber, A., Robinson, J. L., Zhang, B., Pitkin, R. M., Olufemi, M. F., Luk, K. C., et al. (2018) · Nature · doi:10.1038/s41586-018-0104-4 · Cited by 605
Parkinson's disease: Mechanisms, translational models and management strategies
Raza, C., Anjum, R., & Shakeel, N. U. A. (2019) · Life Sciences · doi:10.1016/j.lfs.2019.03.057 · Cited by 603
Metadata
- Authors
- Gorbatyuk, O. S., Li, S., Sullivan, L. F., Chen, W., Kondrikova, G., Manfredsson, F. P., Mandel, R. J., & Muzyczka, N.
- Venue
- Proceedings of the National Academy of Sciences
- Published
- 2008-01-15
- Volume
- 105
- Issue
- 2
- Pages
- 763-768
- ISSN
- 0027-8424 (ISSN-L)
- 1091-6490
- OpenAlex
- W2026455995
- Cited by
- 293
- References
- 28
- FWCI
- 13.55
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.